Faecalibacterium prausnitzii: The Gut's Anti-Inflammatory Workhorse

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

This test measures Faecalibacterium prausnitzii levels in your stool to detect gut microbial imbalance. Low levels have been linked to inflammatory bowel conditions, IBS and increased intestinal inflammation, so identifying them can help guide interventions to support gut health and reduce risk of related digestive problems.

Read more →

Understand what your gut health results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

A spotlight on the gut's anti-inflammatory workhorse

A faecalibacterium prausnitzii test analyzes DNA from a small stool sample to measure the presence and relative abundance of this single, influential gut bacterium within your broader microbiome. Labs typically use modern sequencing (16S rRNA profiling or metagenomics) or a targeted quantitative PCR assay to quantify how much F. prausnitzii is present compared with other microbes. Because this organism is highly oxygen‑sensitive, culture methods are rarely used; DNA techniques are preferred to capture a reliable snapshot. Results reflect your current gut ecosystem rather than a fixed trait, and they can shift with diet, medications, stress, illness, and time.

Why focus on F. prausnitzii? It is one of the most abundant beneficial bacteria in healthy adults and a powerhouse producer of butyrate, a short‑chain fatty acid that feeds colon cells, helps maintain the intestinal barrier, and modulates immune balance. Lower levels have been associated with higher intestinal inflammation and are frequently reported in people with active inflammatory bowel disease, while higher levels tend to track with more stable, diverse microbiomes (though individual variation is common and more research is needed). In short, this marker offers a practical window into your gut’s “anti‑inflammatory engine.”

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

What this single microbe tells you about your gut

Testing F. prausnitzii gives biological context to everyday questions: Are my gut microbes supporting digestion smoothly? Is my intestinal lining well‑nourished, or does it show signs of stress and inflammation? Because F. prausnitzii helps generate butyrate, supports tight junction integrity (the barrier), and influences immune signaling, measuring it can help flag dysbiosis patterns linked to symptoms like irregular stools, cramping, or unexplained bloating. It can also help clarify the ripple effects of real‑life events — from a course of antibiotics or frequent NSAID use to a very low‑carb or very low‑fiber diet — that may transiently depress beneficial species.

Stepping back, the gut microbiome touches metabolism, inflammation, and even mood via the gut–brain axis. Regular, well‑timed checks of key microbes like F. prausnitzii can help you track how interventions such as increasing fiber variety, adding fermentable substrates, improving sleep, or managing stress influence microbial balance and short‑chain fatty acid production over time. The goal isn’t to hit a single “perfect” number but to recognize patterns that align with better digestion, steadier energy, and long‑term health — interpreted with your clinician, not in isolation.

Reading your number in context

Your report typically shows F. prausnitzii as a percentage of total microbial reads or as a quantitative value compared with a reference population. “Balanced” microbiomes often feature a meaningful representation of F. prausnitzii alongside other beneficial genera like Bifidobacterium and Roseburia, plus overall diversity. There is no universal cut‑off that applies to everyone; instead, labs often provide percentile ranges to help you see where you sit relative to similar individuals. A single measurement is informative, but patterns across multiple time points are even more meaningful.

When F. prausnitzii is well‑represented, it usually suggests robust short‑chain fatty acid production — especially butyrate — efficient fiber fermentation, and a calmer inflammatory tone in the colon. This is the microbiome’s version of an efficient “recovery system,” where colon cells are well‑fed and the mucosal barrier stays steady under everyday stressors. Optimal levels vary by geography, diet, and age, so “healthy” is a range, not a fixed target.

When F. prausnitzii is low, it may point to reduced butyrate generation, a thinner nutrient supply for the gut lining, and a tendency toward higher inflammatory signaling. You might also see this pattern in the context of lower overall diversity or shifts toward species associated with inflammation. These findings are not a diagnosis; they highlight functional trends that may respond to changes in fermentable fiber exposure, meal patterns, stress load, or medical evaluation if symptoms persist. For example, increasing fermentable substrates can provide the raw material for butyrate — but the response depends on your whole microbial network, not just one microbe.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

Things that move the reading on their own

Limitations matter. Stool testing measures microbial DNA present in the sample; it does not prove which microbes are alive, active, or producing specific metabolites at that moment. Highly oxygen‑sensitive species like F. prausnitzii can fluctuate with sample handling, and different labs use different assays and reference ranges, so cross‑platform comparisons are imperfect. Day‑to‑day variation also occurs, which is why repeat testing under similar conditions is helpful when you’re tracking change.

What to layer alongside it

The most powerful insights come from context. Pair your F. prausnitzii level with symptom patterns, diet logs, and other biomarkers: stool calprotectin for gut inflammation; CRP for systemic inflammation; metabolic panels if you are exploring links between the microbiome, glycemic control, and weight regulation; and even training load or sleep data if you notice GI shifts around workouts. Together, these layers help you and your clinician translate a single microbial readout into a clear, evidence‑guided plan for digestive comfort and long‑term health — without over‑interpreting a snapshot.

Frequently Asked Questions

References

  1. Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M (2017). Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics. *The ISME Journal*, *11*(4), 841-852. https://doi.org/10.1038/ismej.2016.176
  2. Parsaei M, Sarafraz N, Moaddab SY, Ebrahimzadeh Leylabadlo H (2021). The importance of Faecalibacterium prausnitzii in human health and diseases. *New Microbes and New Infections*, *43*, 100928. https://doi.org/10.1016/j.nmni.2021.100928
  3. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Frontiers in Immunology*, *10*, 277. https://doi.org/10.3389/fimmu.2019.00277
  4. Laudadio I, Fulci V, Palone F, Stronati L, Cucchiara S, Carissimi C (2018). Quantitative assessment of shotgun metagenomics and 16S rDNA amplicon sequencing in the study of human gut microbiome. *OMICS*, *22*(4), 248-254. https://doi.org/10.1089/omi.2018.0013
  5. Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O'Toole PW, Raes J, Hold G, Putignani L, Hvas CL, Nieuwdorp M, Sokol H, Ianiro G, Cammarota G (2025). International consensus statement on microbiome testing in clinical practice. *The Lancet Gastroenterology & Hepatology*, *10*(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey